Keyword Connections

drug development

Journals

20

1 International journal of pharmaceutics

2 PloS one

3 Molecules (Basel, Switzerland)

4 International journal of molecular sciences

5 pakistan journal of pharmaceutical sciences

6 ACS infectious diseases

7 European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

8 current opinion in psychology

9 Drug design, development and therapy

10 globalization and health

11 therapeutic innovation & regulatory science

12 molecular pharmacology

13 the lancet psychiatry

14 clinical pharmacology and therapeutics

15 Alzheimer's research & therapy

16 facial plastic surgery : fps

17 ACS medicinal chemistry letters

18 Clinical trials (London, England)

19 revista do instituto de medicina tropical de sao paulo

20 Precision Medicine Communications

Research Groups

0

No Research Group Connected

Bibliographies

56

1 Comparative docking to distinct G protein-coupled receptor conformations exclusively yields ligands with agonist efficacy.

2 Novel Pyrazole-Containing Compounds Active against .

3 The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions.

4 Preformulation study and initial determination of biological Properties of isopropylidene shikimic acid.

5 Challenges in Alzheimer Disease Drug Discovery and Development: The Role of Modeling, Simulation and Open Data.

6 The role of health technology assessment bodies in shaping drug development.

7 Application of machine learning to predict monomer retention of therapeutic proteins after long term storage.

8 Characterization of Lead Compounds Targeting the Selenoprotein Thioredoxin Glutathione Reductase for Treatment of Schistosomiasis.

9 Transmission control of schistosomiasis mansoni in a low endemicity area through a single intervention with rigorous prospection of infected cases treated with praziquantel: evaluation after 7 years of intervention.

10 Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules.

11 Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health.

12 Potential for Tight Junction Protein-Directed Drug Development Using Claudin Binders and Angubindin-1.

13 Effects of oxygen-glucose deprivation (OGD) on barrier properties and mRNA transcript levels of selected marker proteins in brain endothelial cells/astrocyte co-cultures.

14 Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.

15 in vivo selection of phage for the optical imaging of pc-3 human prostate carcinoma in mice

16 innovative therapeutics

17 from mollusks to medicine: a venomics approach for the discovery and characterization of therapeutics from terebridae peptide toxins

18 rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms

19 development of peptide inhibitors of hiv transmission

20 PhaseÂ I/II study of COVID-19 RNA vaccine BNT162b1 in adults - Nature

21 Now is the time to fix the clinical research workforce crisis.

22 Biological Significance of Imidazole-Based Analogues in New Drug Development.

23 Long-term Engineered Cultures of Primary Mouse Hepatocytes for Strain and Species Comparison Studies During Drug Development.

24 Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.

25 Use of prior knowledge and extrapolation in paediatric drug development: A case study with deferasirox

26 Borrowing from Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines.

27 The "rights" of precision drug development for Alzheimer's disease.

28 Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

29 CNS drug development: Part II: Advances from the 1960s to the 1990s.

30 Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.

31 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

32 Development of a small-scale spray-drying approach for amorphous solid dispersions (ASDs) screening in early drug development.

33 In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.

34 The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence.

35 A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development.

36 The role of health technology assessment bodies in shaping drug development

37 Machine learning for target discovery in drug development

38 Pharmacoinformatics study of Piperolactam A from Piper betle root as new lead for non steroidal anti fertility drug development.

39 Drug development and medical writing in the digital world

40 Proteolysis-targeting chimeras in drug development: A safety perspective.

41 Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

42 Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

43 Animal models of hyperfunctioning parathyroid diseases for drug development

44 multimodal role of amino acids in microbial control and drug development

45 exposure–response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development

46 novel drug development for neuromuscular blockade

47 improving protocol design feasibility to drive drug development economics and performance

48 protein kinases as drug development targets for heart disease therapy

49 lead phytochemicals for anticancer drug development

50 nonsteroidal anti-inflammatory drugs (nsaids): progress in small molecule drug development

51 microbial biotransformation as a tool for drug development based on natural products from mevalonic acid pathway: a review

52 biomarkers and surrogate endpoints: how and when might they impact drug development?

53 application of quality by design in the current drug development

54 liposomes and nanotechnology in drug development: focus on oncotargets

55 Potential drug development candidates for human soil-transmitted helminthiases.

56 Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction.